Detalles de la búsqueda
1.
The prognostic impact of BMI in patients with HR+/HER2- advanced breast cancer: a study of the SONABRE registry.
Breast Cancer Res Treat
; 203(2): 339-349, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37878148
2.
The implementation of CDK 4/6 inhibitors and its impact on treatment choices in HR+/HER2- advanced breast cancer patients: A study of the Dutch SONABRE Registry.
Int J Cancer
; 150(1): 124-131, 2022 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34460112
3.
The initial hormone receptor/HER2 subtype is the main determinator of subtype discordance in advanced breast cancer: a study of the SONABRE registry.
Breast Cancer Res Treat
; 192(2): 331-342, 2022 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-35025003
4.
The influence on quality of life of intermittent scheduling in first- and second-line chemotherapy of patients with HER2-negative advanced breast cancer.
Breast Cancer Res Treat
; 179(3): 677-685, 2020 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-31782032
5.
Breast cancer outcome in relation to bone mineral density and bisphosphonate use: a sub-study of the DATA trial.
Breast Cancer Res Treat
; 180(3): 675-685, 2020 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-32124136
6.
Secondary analyses of the randomized phase III Stop&Go study: efficacy of second-line intermittent versus continuous chemotherapy in HER2-negative advanced breast cancer.
Acta Oncol
; 59(6): 713-722, 2020 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-32141389
7.
Assessment and management of bone health in women with early breast cancer receiving endocrine treatment in the DATA study.
Int J Cancer
; 145(5): 1325-1333, 2019 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30748011
8.
Efficacy of anastrozole after tamoxifen in early breast cancer patients with chemotherapy-induced ovarian function failure.
Int J Cancer
; 145(1): 274-283, 2019 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30588619
9.
Intermittent versus continuous first-line treatment for HER2-negative metastatic breast cancer: the Stop & Go study of the Dutch Breast Cancer Research Group (BOOG).
Breast Cancer Res Treat
; 172(2): 413-423, 2018 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-30121808
10.
Four-year effects of exercise on fatigue and physical activity in patients with cancer.
BMC Med
; 16(1): 86, 2018 06 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-29879968
11.
Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial.
Lancet Oncol
; 18(11): 1502-1511, 2017 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-29031778
12.
Cost-effectiveness of continuous versus intermittent chemotherapy for patients with HER2-negative advanced breast cancer.
Acta Oncol
; 61(5): 619-624, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35139727
13.
A randomized phase 2 study exploring the role of bevacizumab and a chemotherapy-free approach in HER2-positive metastatic breast cancer: The HAT study (BOOG 2008-2003), a Dutch Breast Cancer Research Group trial.
Cancer
; 122(19): 2961-70, 2016 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-27315546
14.
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Lancet
; 385(9980): 1843-52, 2015 May 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-25862517
15.
A phase 1 'window-of-opportunity' trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patients.
BMC Cancer
; 16: 644, 2016 08 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-27535748
16.
Extended adjuvant aromatase inhibition after sequential endocrine therapy in postmenopausal women with breast cancer: follow-up analysis of the randomised phase 3 DATA trial.
EClinicalMedicine
; 58: 101901, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-36992863
17.
Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2- metastatic breast cancer: an observational study of the SONABRE Registry.
Lancet Reg Health Eur
; 26: 100573, 2023 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-36895447
18.
The prognostic and predictive effect of body mass index in hormone receptor-positive breast cancer.
JNCI Cancer Spectr
; 7(6)2023 10 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-37991939
19.
Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.
N Engl J Med
; 360(6): 563-72, 2009 Feb 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-19196673
20.
The role of chemotherapy in treatment of advanced breast cancer: an overview for clinical practice.
Crit Rev Oncol Hematol
; 153: 102988, 2020 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-32599374